Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Calcium Channel Blockers May Improve Chemotherapy Response
Clinical Breakthroughs

Calcium Channel Blockers May Improve Chemotherapy Response

By Melissa RohmanJun 21, 2022
Share
Facebook Twitter Email
Thao Pham, PhD, research assistant professor of Medicine in the Division of Hematology and Oncology and a co-author of the study published in the Proceedings of the National Academy of Sciences. 

Calcium channel blockers may improve treatment for pancreatic cancer patients receiving gemcitabine-based chemotherapy, according to recent findings published in the Proceedings of the National Academy of Sciences. 

“These exciting data suggest that the addition of a calcium channel blocker to gemcitabine may have some benefits, especially since calcium channel blockers have a very favorable toxicity profile, are low cost and are readily available,” said Thao Pham, PhD, research assistant professor of Medicine in the Division of Hematology and Oncology and a co-author of the study.

Hidayatullah Munshi, MD, the Robert and Lora Lurie Professor of Medicine, was also a co-author of the study.

Pancreatic cancer generally has very poor survival rates due in part to resistance to chemotherapy. While palliative chemotherapy can improve patients’ symptoms and overall quality of life, more effective treatment options are desperately needed.

In the current study, the investigators sought to identify new treatment strategies to prevent or overcome resistance to gemcitabine, one of the most widely used pancreatic cancer drugs.

Using single-cell RNA sequencing and high-throughput proteomic analysis to study pancreatic cell lines treated with gemcitabine, the team discovered a subset of gemcitabine-resistant tumor cells with enhanced calcium-dependent calmodulin signaling. Calmodulin, a calcium-binding messenger protein, is known to promote the expression of the oncogene KRAS, which is among the most commonly mutated oncogenes found in pancreatic tumors.

“We learned a couple of things here,” Pham said. “First, given a population of cancer cells, there are always some subpopulations that are intrinsically resistant to gemcitabine — they display lower stress and do not die as much as the corresponding sensitive subpopulations. Second, these subpopulations of resistant cells appear to upregulate genes associated with calcium ion transport, binding and signaling.”

They also discovered that pharmacologically inhibiting calcium-dependent calmodulin activation in pancreatic cancer cell lines decreased drug-resistant phenotypes. Additional single-cell RNA sequencing identified that this was due to impaired activation of the RAS/ERK signaling pathway.

Hidayatullah Munshi, MD, the Robert and Lora Lurie Professor of Medicine, was also a co-author of the study.

Using calcium channel blocker drugs, such as amlodipine, in vitro and in orthotopic xenografts and transgenic mouse models of pancreatic cancer treated with gemcitabine, the investigators were able to inhibit RAS/ERK signaling, suggesting an enhanced therapeutic response to gemcitabine.

The findings suggest that calcium-dependent calmodulin signaling is a protective mechanism used by pancreatic cancer cells in response to gemcitabine treatment and that calcium channel blockers may provide clinical benefit to patients.

Furthermore, understanding how these cancer cells become gemcitabine-resistant can provide insight into prolonging treatment response and overcoming treatment resistance altogether, according to Pham.

“Next steps include a randomized clinical trial investigating whether adding calcium channel blockers such as amlodipine or nifedipine can help extend survival for patients receiving gemcitabine treatment,” Pham said.

Pham and Munshi are both members of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

This work was partially supported by the National Institutes of Health grant R21CA255291 and the Veterans Affairs Merit Award I01BX002922.

Cancer Medicine Research
Share. Facebook Twitter Email

Related Posts

Investigating the Connection Between Steps and Heart Disease Risk

Feb 1, 2023

Transforming the Way Cancer Vaccines are Designed and Made

Jan 30, 2023

Calcium Channels Regulate Neuroinflammation and Neuropathic Pain 

Jan 27, 2023

Comments are closed.

Latest News

Investigating the Connection Between Steps and Heart Disease Risk

Feb 1, 2023

Medical School Faculty Named AAAS Fellows

Jan 31, 2023

Transforming the Way Cancer Vaccines are Designed and Made

Jan 30, 2023

Calcium Channels Regulate Neuroinflammation and Neuropathic Pain 

Jan 27, 2023

Changes in Medical School Leadership

Jan 26, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
Feinberg_In_Vivo_20221209_tcrawford-24
Feinberg_In_Vivo_20221209_tcrawford-16
Feinberg_In_Vivo_20221209_tcrawford-14
Feinberg_In_Vivo_20221209_tcrawford-5
Feinberg_In_Vivo_20221209_tcrawford-6
Feinberg_In_Vivo_20221209_tcrawford-10
Feinberg_In_Vivo_20221209_tcrawford-8
Feinberg_In_Vivo_20221209_tcrawford-18
Feinberg_In_Vivo_20221209_tcrawford
Feinberg_In_Vivo_20221209_tcrawford-23
Feinberg_In_Vivo_20221209_tcrawford-25
Feinberg_In_Vivo_20221209_tcrawford-26

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.